MSK Department of Medicine
@mskdeptofmed.bsky.social
The official account of @mskcancercenter.bsky.social's Department of Medicine. Chair/Dept. Head: Deb Schrag
Reposted by MSK Department of Medicine
New research from MSK sheds new light on how the gut protects itself by sensing gut bacteria; finds a subtype of #glioma-associated macrophages that appear to play a pivotal role in progression; and more.
MSK Research Highlights, January 20, 2026
New MSK research sheds new light on how the gut protects itself by sensing gut bacteria; finds a subtype of glioma-associated macrophages that appear to play a pivotal role in progression; and demonst...
www.mskcc.org
January 26, 2026 at 2:34 PM
New research from MSK sheds new light on how the gut protects itself by sensing gut bacteria; finds a subtype of #glioma-associated macrophages that appear to play a pivotal role in progression; and more.
Reposted by MSK Department of Medicine
Medical oncologist @drmiguelperales.bsky.social, Chief of the Adult Bone Marrow Transplant Service at MSK, shares 10 reasons why MSK's BMT program continues to be a leader in the field of transplantation. bit.ly/3NnAZQI
January 14, 2026 at 9:23 PM
Medical oncologist @drmiguelperales.bsky.social, Chief of the Adult Bone Marrow Transplant Service at MSK, shares 10 reasons why MSK's BMT program continues to be a leader in the field of transplantation. bit.ly/3NnAZQI
Congrats to Eytan Stein & collaborators on receiving "2025 Paper of the Year” from @jco-asco.bsky.social for their study evaluating revumenib for acute #leukemia with a KMT2A translocation. Study results led to the drug's FDA approval in 2024. @mskcancercenter.bsky.social
➡️ https://bit.ly/3LH5G2R
➡️ https://bit.ly/3LH5G2R
FDA Approves Revumenib, a Menin Inhibitor, for Aggressive Leukemia
Based on a clinical trial led by an MSK investigator, the FDA has approved revumenib (Revuforj®) for patients 1-year-old and older who have leukemia that has come back after treatment and whose cancer...
www.mskcc.org
January 14, 2026 at 7:28 PM
Congrats to Eytan Stein & collaborators on receiving "2025 Paper of the Year” from @jco-asco.bsky.social for their study evaluating revumenib for acute #leukemia with a KMT2A translocation. Study results led to the drug's FDA approval in 2024. @mskcancercenter.bsky.social
➡️ https://bit.ly/3LH5G2R
➡️ https://bit.ly/3LH5G2R
Reposted by MSK Department of Medicine
Congratulations to Dr. Ross Levine (@rosslevinemd.bsky.social), MSK's Chief Scientific Officer, who was appointment editor-in-chief of Blood Cancer Discovery, published by @theaacr.bsky.social.
Learn more: bit.ly/4qR5Qn1
Learn more: bit.ly/4qR5Qn1
January 13, 2026 at 4:09 PM
Congratulations to Dr. Ross Levine (@rosslevinemd.bsky.social), MSK's Chief Scientific Officer, who was appointment editor-in-chief of Blood Cancer Discovery, published by @theaacr.bsky.social.
Learn more: bit.ly/4qR5Qn1
Learn more: bit.ly/4qR5Qn1
Collaborators Eric Van Cutsem, Yelena Janjigian, & Kohei Shitara caught up at #GI26. Dr. Janjigian shared a trial in progress of a 1st line combination for HER2-low #gastriccancer, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma. @mskcancercenter.bsky.social.
bit.ly/4aSddGo
bit.ly/4aSddGo
January 8, 2026 at 10:58 PM
Collaborators Eric Van Cutsem, Yelena Janjigian, & Kohei Shitara caught up at #GI26. Dr. Janjigian shared a trial in progress of a 1st line combination for HER2-low #gastriccancer, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma. @mskcancercenter.bsky.social.
bit.ly/4aSddGo
bit.ly/4aSddGo
Coming up at #GI26, Dr. Geoffrey Ku will give a medical oncologist's perspective on the role of local and systemic treatments in metastatic #gastriccancer and #gastroesophagealcancer @mskcancercenter.bsky.social #GICancers @ascocancer.bsky.social
3:45 – 5 p.m. PST | Level 3, Room 3001
3:45 – 5 p.m. PST | Level 3, Room 3001
January 8, 2026 at 9:26 PM
Coming up at #GI26, Dr. Geoffrey Ku will give a medical oncologist's perspective on the role of local and systemic treatments in metastatic #gastriccancer and #gastroesophagealcancer @mskcancercenter.bsky.social #GICancers @ascocancer.bsky.social
3:45 – 5 p.m. PST | Level 3, Room 3001
3:45 – 5 p.m. PST | Level 3, Room 3001
We're excited for @ascocancer.bsky.social #GI26! Stop by Dr. Steve Maron's poster to learn about a phase 2 trial of amivantamab for EGFR- or MET-amplified #gastroesophageal #adenocarcinoma. @mskcancercenter.bsky.social #GICancer
TODAY | 11:30 – 1 p.m. PST
Learn more: bit.ly/49cfzyr
TODAY | 11:30 – 1 p.m. PST
Learn more: bit.ly/49cfzyr
January 8, 2026 at 3:59 PM
We're excited for @ascocancer.bsky.social #GI26! Stop by Dr. Steve Maron's poster to learn about a phase 2 trial of amivantamab for EGFR- or MET-amplified #gastroesophageal #adenocarcinoma. @mskcancercenter.bsky.social #GICancer
TODAY | 11:30 – 1 p.m. PST
Learn more: bit.ly/49cfzyr
TODAY | 11:30 – 1 p.m. PST
Learn more: bit.ly/49cfzyr
Research co-led by MSK scientists found a gene variant that may reduce the risk of developing certain #bloodcancers associated with #clonalhematopoiesis. Learn more about how @mskcancercenter.bsky.social is leading the way in CH research and treatment.
Also check out our CH clinic: bit.ly/49szicf
Also check out our CH clinic: bit.ly/49szicf
Scientists have known for decades that there are gene mutations that increase your risk of developing cancer. But there is also a genetic variant that could reduce the risk of developing certain #bloodcancers, according to new research co-led by scientists from MSK.
Learn more: bit.ly/4sIJ5DQ
Learn more: bit.ly/4sIJ5DQ
January 7, 2026 at 7:33 PM
Research co-led by MSK scientists found a gene variant that may reduce the risk of developing certain #bloodcancers associated with #clonalhematopoiesis. Learn more about how @mskcancercenter.bsky.social is leading the way in CH research and treatment.
Also check out our CH clinic: bit.ly/49szicf
Also check out our CH clinic: bit.ly/49szicf
Congrats to Dr. Deb Schrag, the Department of Medicine's fearless leader, on being elected as the 2027–2028 @ascocancer.bsky.social President! She has devoted her career to accelerating progress for people with #cancer, and we can't wait to witness the amazing things she will do next. #oncology
Congratulations to Dr. Deb Schrag, a gastrointestinal medical oncologist and Chair of the Department of Medicine at MSK, on being elected as the 2027-28 President of the @ascocancer.bsky.social.
Read more: bit.ly/3N8Nf7q
Read more: bit.ly/3N8Nf7q
December 19, 2025 at 5:08 PM
Congrats to Dr. Deb Schrag, the Department of Medicine's fearless leader, on being elected as the 2027–2028 @ascocancer.bsky.social President! She has devoted her career to accelerating progress for people with #cancer, and we can't wait to witness the amazing things she will do next. #oncology
Reposted by MSK Department of Medicine
🚨 UPDATE: The @fda.gov has approved a new therapy for #marginalzonelymphoma. The approval is based on results from a phase 2 clinical trial led by Dr. Lia Palomba, a hematologist-oncologist at MSK.
Learn more: bit.ly/4iVd9Y6
Learn more: bit.ly/4iVd9Y6
December 15, 2025 at 8:22 PM
🚨 UPDATE: The @fda.gov has approved a new therapy for #marginalzonelymphoma. The approval is based on results from a phase 2 clinical trial led by Dr. Lia Palomba, a hematologist-oncologist at MSK.
Learn more: bit.ly/4iVd9Y6
Learn more: bit.ly/4iVd9Y6
Reposted by MSK Department of Medicine
MSK genitourinary oncologist Dr. Rosenberg has led multiple clinical trials testing enfortumab vedotin alone or in combination with others for #bladdercancer. Learn more ⬇️
Bladder Cancer Therapy Enfortumab Vedotin (Padcev) Approved by FDA for More Patients
A powerful therapy called an antibody-drug conjugate has been approved by the FDA for more people with bladder cancer.
www.mskcc.org
December 16, 2025 at 7:10 PM
MSK genitourinary oncologist Dr. Rosenberg has led multiple clinical trials testing enfortumab vedotin alone or in combination with others for #bladdercancer. Learn more ⬇️
Don't miss Dr. Zsofia Stadler's presentation "Identification of inherited #cancer syndromes: Re-defining early-onset cancers" at #AACRearlyonset25. Andrea Cercek is the conference co-chair. @mskcancercenter.bsky.social @theaacr.bsky.social
TODAY | 11:30 a.m. ET
bit.ly/4qlOXB1
TODAY | 11:30 a.m. ET
bit.ly/4qlOXB1
December 13, 2025 at 2:00 PM
Don't miss Dr. Zsofia Stadler's presentation "Identification of inherited #cancer syndromes: Re-defining early-onset cancers" at #AACRearlyonset25. Andrea Cercek is the conference co-chair. @mskcancercenter.bsky.social @theaacr.bsky.social
TODAY | 11:30 a.m. ET
bit.ly/4qlOXB1
TODAY | 11:30 a.m. ET
bit.ly/4qlOXB1
At the @theaacr.bsky.social special conference on the rise of early-onset #cancers, Dr. Luis Diaz will present in a session about opportunities for early interception. Andrea Cercek is the conference co-chair. @mskcancercenter.bsky.social #AACRearlyonset25
TODAY | 11:10 a.m. ET
bit.ly/4qlOXB1
TODAY | 11:10 a.m. ET
bit.ly/4qlOXB1
December 13, 2025 at 1:00 PM
At the @theaacr.bsky.social special conference on the rise of early-onset #cancers, Dr. Luis Diaz will present in a session about opportunities for early interception. Andrea Cercek is the conference co-chair. @mskcancercenter.bsky.social #AACRearlyonset25
TODAY | 11:10 a.m. ET
bit.ly/4qlOXB1
TODAY | 11:10 a.m. ET
bit.ly/4qlOXB1
Reposted by MSK Department of Medicine
Dr. Jun Mao, the Integrative Medicine and Wellness Service Chief at MSK, presented research on the benefits of acupuncture for #breastcancer patients who experience cancer-related cognitive impairment at the 2025 @sabcs.bsky.social .
Learn more: bit.ly/4aeZAkg
Learn more: bit.ly/4aeZAkg
December 12, 2025 at 6:09 PM
Dr. Jun Mao, the Integrative Medicine and Wellness Service Chief at MSK, presented research on the benefits of acupuncture for #breastcancer patients who experience cancer-related cognitive impairment at the 2025 @sabcs.bsky.social .
Learn more: bit.ly/4aeZAkg
Learn more: bit.ly/4aeZAkg
Reposted by MSK Department of Medicine
TERN-701 Elicits Deep Responses in Heavily Pretreated CP-CML @mdanderson.bsky.social @ash.hematology.org #ASH25 #leusm #oncology www.onclive.com/view/tern-70...
TERN-701 Elicits Deep Responses in Heavily Pretreated CP-CML | OncLive
TERN-701 yielded a high response rate with deep molecular responses in heavily pretreated chronic phase chronic myeloid leukemia.
www.onclive.com
December 12, 2025 at 5:19 PM
TERN-701 Elicits Deep Responses in Heavily Pretreated CP-CML @mdanderson.bsky.social @ash.hematology.org #ASH25 #leusm #oncology www.onclive.com/view/tern-70...
Reposted by MSK Department of Medicine
Results from #SABCS25: A trial, reported by breast cancer medical oncologist @breastcancerdoc.bsky.social, show that a new treatment continues to be effective at stopping advanced #breastcancer from progressing in some people with tumors that have grown resistant to standard therapy.
bit.ly/3MGgZs6
bit.ly/3MGgZs6
December 12, 2025 at 7:38 PM
Results from #SABCS25: A trial, reported by breast cancer medical oncologist @breastcancerdoc.bsky.social, show that a new treatment continues to be effective at stopping advanced #breastcancer from progressing in some people with tumors that have grown resistant to standard therapy.
bit.ly/3MGgZs6
bit.ly/3MGgZs6
Reposted by MSK Department of Medicine
HAPPENING SOON at #SABCS25: MSK breast surgeon Dr. Giacomo Montagna will present research on the de-escalation of axillary surgery after NAC in clinically node positive patients.
@sabcs.bsky.social.
🗓️: December 11 at 1 p.m. (CST)
@sabcs.bsky.social.
🗓️: December 11 at 1 p.m. (CST)
December 11, 2025 at 6:06 PM
HAPPENING SOON at #SABCS25: MSK breast surgeon Dr. Giacomo Montagna will present research on the de-escalation of axillary surgery after NAC in clinically node positive patients.
@sabcs.bsky.social.
🗓️: December 11 at 1 p.m. (CST)
@sabcs.bsky.social.
🗓️: December 11 at 1 p.m. (CST)
Reposted by MSK Department of Medicine
TODAY at the #SABCS25: Dr. Jun Mao, an integrative medicine specialist at MSK, will present research on the effects of acupuncture versus sham acupuncture and usual care on cancer-related cognitive difficulties among #breastcancer survivors. @sabcs.bsky.social
🗓️: December 12 at 9 a.m. (CST)
🗓️: December 12 at 9 a.m. (CST)
December 12, 2025 at 2:41 PM
TODAY at the #SABCS25: Dr. Jun Mao, an integrative medicine specialist at MSK, will present research on the effects of acupuncture versus sham acupuncture and usual care on cancer-related cognitive difficulties among #breastcancer survivors. @sabcs.bsky.social
🗓️: December 12 at 9 a.m. (CST)
🗓️: December 12 at 9 a.m. (CST)
We're excited for AACR Special Conference in Cancer Research: The Rise in Early-Onset Cancers! @karunamdphd.bsky.social will discuss the role of pks⁺ E. coli in early-onset #colorectalcancer. @theaacr.bsky.social @mskcancercenter.bsky.social #AACRearlyonset25
TODAY | 3:20 p.m. ET
bit.ly/4qlOXB1
TODAY | 3:20 p.m. ET
bit.ly/4qlOXB1
December 12, 2025 at 5:05 PM
We're excited for AACR Special Conference in Cancer Research: The Rise in Early-Onset Cancers! @karunamdphd.bsky.social will discuss the role of pks⁺ E. coli in early-onset #colorectalcancer. @theaacr.bsky.social @mskcancercenter.bsky.social #AACRearlyonset25
TODAY | 3:20 p.m. ET
bit.ly/4qlOXB1
TODAY | 3:20 p.m. ET
bit.ly/4qlOXB1
#SABCS25 posters! Visit Dr. Tiffany Traina to learn about the safety analysis of first-line datopotamab deruxtecan vs chemo for locally recurrent inoperable or metastatic triple negative #breastcancer. #bcsm @sabcs.bsky.social @mskcancercenter.bsky.social
⏰ 12:30–2 p.m. CST
bit.ly/4puGBqn
⏰ 12:30–2 p.m. CST
bit.ly/4puGBqn
December 12, 2025 at 3:02 PM
#SABCS25 posters! Visit Dr. Tiffany Traina to learn about the safety analysis of first-line datopotamab deruxtecan vs chemo for locally recurrent inoperable or metastatic triple negative #breastcancer. #bcsm @sabcs.bsky.social @mskcancercenter.bsky.social
⏰ 12:30–2 p.m. CST
bit.ly/4puGBqn
⏰ 12:30–2 p.m. CST
bit.ly/4puGBqn
Coming up at #SABCS25: @breastcancerdoc.bsky.social will present updated results from the phase 3 EMBER-3 trial of imlunestrant with or without abemaciclib for advanced #breastcancer. #bcsm @sabcs.bsky.social @mskcancercenter.bsky.social
TODAY | 9 a.m.–11:30 a.m. CST
Learn more: bit.ly/4rLjFFb
TODAY | 9 a.m.–11:30 a.m. CST
Learn more: bit.ly/4rLjFFb
December 12, 2025 at 1:01 PM
Coming up at #SABCS25: @breastcancerdoc.bsky.social will present updated results from the phase 3 EMBER-3 trial of imlunestrant with or without abemaciclib for advanced #breastcancer. #bcsm @sabcs.bsky.social @mskcancercenter.bsky.social
TODAY | 9 a.m.–11:30 a.m. CST
Learn more: bit.ly/4rLjFFb
TODAY | 9 a.m.–11:30 a.m. CST
Learn more: bit.ly/4rLjFFb
Join @sherryshenmd.bsky.social for a presentation on adjuvant therapy decisions in HR+HER2- #breastcancer in the era of axillary de-escalation. #bcsm @sabcs.bsky.social @mskcancercenter.bsky.social #SABCS25
TODAY | 1 p.m.–2:15 p.m. CST
Learn more: bit.ly/4rPRhl8
TODAY | 1 p.m.–2:15 p.m. CST
Learn more: bit.ly/4rPRhl8
December 11, 2025 at 4:02 PM
Join @sherryshenmd.bsky.social for a presentation on adjuvant therapy decisions in HR+HER2- #breastcancer in the era of axillary de-escalation. #bcsm @sabcs.bsky.social @mskcancercenter.bsky.social #SABCS25
TODAY | 1 p.m.–2:15 p.m. CST
Learn more: bit.ly/4rPRhl8
TODAY | 1 p.m.–2:15 p.m. CST
Learn more: bit.ly/4rPRhl8
Reposted by MSK Department of Medicine
HAPPENING SOON at #SABCS25: MSK breast oncologist and early drug development specialist Dr. @breastcancerdoc.bsky.social will present results from her ASCENT-07 clinical trial for patients with HR+/HER2 metastatic #breastcancer. @sabcs.bsky.social
🗓️: December 10 at 9:30 am (CST)
🗓️: December 10 at 9:30 am (CST)
December 10, 2025 at 2:17 PM
HAPPENING SOON at #SABCS25: MSK breast oncologist and early drug development specialist Dr. @breastcancerdoc.bsky.social will present results from her ASCENT-07 clinical trial for patients with HR+/HER2 metastatic #breastcancer. @sabcs.bsky.social
🗓️: December 10 at 9:30 am (CST)
🗓️: December 10 at 9:30 am (CST)
Reposted by MSK Department of Medicine
@breastcancerdoc.bsky.social, a breast medical oncologist at MSK, presented results from the ASCENT-07 clinical trial at the @sabcs.bsky.social.
The phase 3 clinical trial, which tested sacituzumab govitecan-hziy as the first treatment after endocrine therapy for people... (cont.)
bit.ly/4pBgRZC
The phase 3 clinical trial, which tested sacituzumab govitecan-hziy as the first treatment after endocrine therapy for people... (cont.)
bit.ly/4pBgRZC
December 10, 2025 at 5:36 PM
@breastcancerdoc.bsky.social, a breast medical oncologist at MSK, presented results from the ASCENT-07 clinical trial at the @sabcs.bsky.social.
The phase 3 clinical trial, which tested sacituzumab govitecan-hziy as the first treatment after endocrine therapy for people... (cont.)
bit.ly/4pBgRZC
The phase 3 clinical trial, which tested sacituzumab govitecan-hziy as the first treatment after endocrine therapy for people... (cont.)
bit.ly/4pBgRZC